Shenzhen jymmed technology Co., Ltd. (Hereñafter referred to as jmed) in statutum est in MMIX, specialiter in investigationis, progressionem, productio et venditionesque peptides et peptide actis products. Et unum investigationis centrum et tres major productionem bases, jymmed est unus de maxima effectrix chemica synthesized peptide apis in Sinis. In Company scriptor core R & D quadrigis quatenus super XX annos experientia in peptide industria et feliciter Transierunt FDA inspectionibus bis. Jymmed scriptor comprehensive et efficens peptide industrialization ratio praebet customers a plena range of muneris, comprehendo ad progressionem et productionem therapeutic peptides, VETERINARIUS peptides, antimicrobial peptides, et regulatory peptides, tum adnotatione et regulatory Support.

Pelagus res actiones

1.Gomestis et International Registration of Peptide Apis

2.veterinary et COLOR peptides

3.Custom peptides et Cro, CMO, OEM Services

4.pdc medicamina (peptide-radionuclide, peptide-parva molecule, peptide, dapibus, peptide-rna)

Insuper et Tirzepatide, Jymed est Submitted Registration Fiction cum FDA et Cde pro pluribus aliis API products, comprehendo in currently popularibus GLP-1ra classis ut semaglutide et Liraglutide. Future customers per jymmed scriptor products poterit ad directe referat ad Cde adnotatione numero vel DMF file numerus cum submittendo adnotatione applications ad FDA aut Cde. Hoc autem significantly reducere tempus requiritur ad parat application documenta, tum iudicium et tempus et sumptus of productum recensionem.